Compare Abbott India with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DR. REDDYS LAB - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DR. REDDYS LAB ABBOTT INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 56.4 31.8 177.7% View Chart
P/BV x 16.7 3.7 450.4% View Chart
Dividend Yield % 0.4 0.6 64.6%  

Financials

 ABBOTT INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
DR. REDDYS LAB
Mar-19
ABBOTT INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8,8342,875 307.3%   
Low Rs5,4581,888 289.1%   
Sales per share (Unadj.) Rs1,731.1930.2 186.1%  
Earnings per share (Unadj.) Rs211.9117.4 180.5%  
Cash flow per share (Unadj.) Rs219.9185.8 118.4%  
Dividends per share (Unadj.) Rs65.0020.00 325.0%  
Dividend yield (eoy) %0.90.8 108.3%  
Book value per share (Unadj.) Rs945.2844.4 111.9%  
Shares outstanding (eoy) m21.25166.07 12.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.6 161.2%   
Avg P/E ratio x33.720.3 166.3%  
P/CF ratio (eoy) x32.512.8 253.5%  
Price / Book Value ratio x7.62.8 268.1%  
Dividend payout %30.717.0 180.1%   
Avg Mkt Cap Rs m151,848395,496 38.4%   
No. of employees `0003.522.0 15.9%   
Total wages/salary Rs m4,35633,562 13.0%   
Avg. sales/employee Rs Th10,555.57,032.8 150.1%   
Avg. wages/employee Rs Th1,249.91,527.9 81.8%   
Avg. net profit/employee Rs Th1,292.2887.7 145.6%   
INCOME DATA
Net Sales Rs m36,786154,482 23.8%  
Other income Rs m1,1333,375 33.6%   
Total revenues Rs m37,919157,857 24.0%   
Gross profit Rs m6,04731,782 19.0%  
Depreciation Rs m16911,348 1.5%   
Interest Rs m23889 2.5%   
Profit before tax Rs m6,98922,920 30.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4853,858 64.4%   
Profit after tax Rs m4,50319,500 23.1%  
Gross profit margin %16.420.6 79.9%  
Effective tax rate %35.616.8 211.3%   
Net profit margin %12.212.6 97.0%  
BALANCE SHEET DATA
Current assets Rs m27,610111,101 24.9%   
Current liabilities Rs m8,56958,973 14.5%   
Net working cap to sales %51.833.7 153.4%  
Current ratio x3.21.9 171.0%  
Inventory Days Days6079 75.9%  
Debtors Days Days2794 29.1%  
Net fixed assets Rs m1,057101,245 1.0%   
Share capital Rs m213830 25.6%   
"Free" reserves Rs m19,873139,406 14.3%   
Net worth Rs m20,086140,236 14.3%   
Long term debt Rs m022,000 0.0%   
Total assets Rs m29,409224,656 13.1%  
Interest coverage x311.626.8 1,163.5%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.30.7 181.9%   
Return on assets %15.49.1 169.6%  
Return on equity %22.413.9 161.2%  
Return on capital %34.914.9 233.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36988,673 0.4%   
Fx outflow Rs m4,91819,104 25.7%   
Net fx Rs m-4,54969,569 -6.5%   
CASH FLOW
From Operations Rs m4,99128,704 17.4%  
From Investments Rs m-2,570-7,727 33.3%  
From Financial Activity Rs m-1,428-21,326 6.7%  
Net Cashflow Rs m993-314 -316.3%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.4 146.3%  
FIIs % 0.1 35.3 0.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.1 15.3 111.8%  
Shareholders   18,270 75,885 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PFIZER  TORRENT PHARMA  FRESENIUS KABI ONCO.  WYETH LTD  GSK PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 500 Points; Kotak Mahindra Bank & IndusInd Bank Top Losers(12:30 pm)

Share markets in India are presently trading on a negative note, as investors worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Apr 3, 2020 03:23 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - J.B.CHEMICALS COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS